Gyre Therapeutics (GYRE) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Gyre Therapeutics

NasdaqCM•Healthcare•Biotechnology

$7.18+0.48(0.07%)After hours

Market Cap

$722.58M

P/S

6.1x

P/B

6.7x

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

How this company scores

AverageMetricSide Score: 42/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (6/25).

Profitability8/25

Growth13/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Growing revenueLong cash runwayInterest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 64.6x5y range 17.3x – 75.0x

Currently near its 7-quarter median.

P/S · 6.1x5y range 5.3x – 318.1x

Currently below its 17-quarter median.

P/B · 6.7x5y range 6.0x – 77.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 282.7% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $722.58M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $119.38M
Q. Revenue: $29.11M
TTM EBITDA: $-13.21M
TTM Op. Income: $-16.68M
Q. Op. Income: $-14.36M
TTM Net Income: $-19.56M
Q. Net Income: $-14.27M
EPS: $-0.12
Shares Out.: $100.64M

$119.38M in TTM revenue grew 16.8% YoY, reaching $29.11M last quarter. TTM EBITDA of $-13.21M and TTM operating income of $-16.68M show growth is flowing through to the bottom line. However, net income is negative at $19.56M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 92.4%
EBITDA Margin: -44.3%
Op. Margin: -49.3%
Net Margin: -49.0%

Op. margin of -49.3% is down 57.5% YoY — costs are rising relative to revenue. Net margin at -49.0% and gross margin of 92.4% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 6.1x
P/B Ratio: 6.7x

P/S of 6.1x and P/B of 6.7x. Over the past year, P/E is up 6% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $199.25M
Cash: $43.29M
Long-Term Debt: N/A
Book Value: $107.93M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-16.73M
TTM Free Cash Flow: $-15.75M
FCF Margin: -13.2%
FCF / Net Income: 0.8

TTM FCF of $-15.75M on $-16.73M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 19835% — a weakening trend.